Introduction {#sec0005}
============

The World Health Organization (WHO) recently published guidance on adjusting public health and social measures for the next phase of the coronavirus disease 2019 (COVID-19) response, declaring that there is no evidence that people who have recovered and have antibodies are protected from a second infection ([@bib0010]). Most studies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have shown that people who have recovered from COVID-19 have antibodies to the virus. However, some of these patients have had very low levels of neutralizing antibodies in their blood, which could potentially expose them to a second infection ([@bib0015]). No study has determined whether the presence of antibodies to SARS-CoV-2 confers immunity to second infection; however, to date, no human reinfections with SARS-CoV-2 have been confirmed ([@bib0005]).

Materials and methods {#sec0010}
=====================

To approach this dilemma from a clinical point of view, we would like to report the results of preliminary monitoring surveillance based on a large cohort of individuals who had recovered from COVID-19.

In this prospective multicentre cohort study, all adult patients with confirmed COVID-19 who were discharged from two hospitals in an area of Italy severely affected by the infection (Ospedale ASST Ovest Milanese of Legnano and Magenta, Milan, Lombardy) were investigated within 3 months. Telephone follow-up was conducted at 1 and 2 months and clinical contact was made within 3 months, initiated by the health professionals at the hospitals involved. Demographic, clinical, radiological, and laboratory data were recorded in the electronic medical records and updated. The local institutional review board approved this study and waived the need for informed consent.

Results {#sec0015}
=======

Of 1081 patients included in this study, 804 (74.3%) were discharged alive and with at least two consecutive negative swabs. Follow-up data were obtained for all of these patients ([Figure 1](#fig0005){ref-type="fig"} ). In particular, we reviewed the signs and symptoms of acute SARS-CoV-2 infection, extending our attention not only to a general survey and the respiratory system, but also to the skin, cardiovascular system, gastrointestinal system, and central nervous system. At 1 and 2 months, none of the patients had died, and none reported any signs of recurrence of the infection during either telephone interview or at the clinical visit. Twenty-four patients were hospitalized again for acute diseases not closely related to SARS-CoV-2 ([Figure 1](#fig0005){ref-type="fig"}). Oropharyngeal swabs obtained from these patients were all negative.Figure 1Cohort and follow-up. ★ Major gastrointestinal bleeding during anticoagulant therapy (*n* = 3), acute ischemic stroke (*n* = 2), NSTEMI (*n* = 2), urinary sepsis (*n* = 4), chronic obstructive pulmonary disease exacerbation (*n* = 5), heart failure (*n* = 4), diabetic ketoacidosis (*n* = 1), delirium psychosis (*n* = 3).Figure 1

Discussion {#sec0020}
==========

Although the follow-up of the patients was short and incomplete, and immunological data are lacking, which will be investigated over the next months, this clinical observation study appears to confirm two basic points: that reinfection is very unlikely and that any antibody immunity protects against recurrence, at least in the short term.
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